Contributor Page
Oblon, McClelland, Maier & Neustadt, L.L.P
Email  |  Website  |  Articles
Contact Details
Tel: +1 703 413 3000
Fax: +1 703 413 2220
1940 Duke Street
VA 22314
United States
By Oblon, McClelland, Maier & Neustadt, L.L.P
On September 23, 2019, the USPTO issued the following statement:
By W. Todd Baker
In many cases, a successful forecast of a technological trend can be accomplished by just following the patents.
By Richard D. Kelly
Previously, ADT filed for inter partes review of Applied's ‘817 patent, challenging the validity of the patent's claims for obviousness.
By Richard D. Kelly
The doctrine of equivalents is an equitable exception to the basic concept that the patent claims define the limit of claim protection.
By David M. Longo
The title above refers to a lyric from a 1998 song by Eve 6, although they used the word "cabinet" instead of "chair."
By Matthew E. Barnet
The majority expressed caution about the breadth of its holding, in particular about concerns that the holding could harm the nascent field of personalized medicine.
By Marina I. Miller
Claim 25 of Application No. 12/393,833, continued from the '803 application, also recited using random MPS to determine fetal aneuploidy.
By Teddy S. Gron
Teddy Gron wrote an article entitled "Patently Obvious?" featured in the September issue of the Illinois State Bar Association magazine.
By Lisa M. Mandrusiak
Design patents are very different from utility patents in that design patents only protect the ornamental features of an invention. In contrast to utility patents, the design is defined
By Oblon, McClelland, Maier & Neustadt, L.L.P
On August 27, 2019, the USPTO issued a Federal Register Notice requesting comments on artificial intelligence patent issues to assist in "evaluating whether further examination guidance is needed to promote ...
By Daniel J. Pereira
There's no prohibition on patenting illegal substances; however, if marijuana is illegal under federal law, how can a patent holder enforce such a right?
By Yuki Onoe
「特定の」塩の組み合わせを強調して反論を行ったために包袋禁反言(審査経過に基づくエストッペル)が適用された事例 出願審査におい&#
By Daniel J. Pereira
Nalpropion Pharmaceuticals, Inc. v Actavis Laboratories FL, Inc (Fed. Cir. Aug. 15, 2019) is a precedential opinion written by Judge Lourie with Judge Wallach and a dissent from Judge Prost
By J. Derek Mason
Manufacturers need to protect products they produce from counterfeits, says J. Derek Mason, partner with Oblon
By Richard D. Kelly
Every innovative pharma company faces the same challenge, how to delay the patent cliff. The existence of the "skinny viii" (21 U.S.C. § 355(j)(2)(A)(viii)) makes developing additional FDA